Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
SOUTH SAN FRANCISCO, Calif., Aug. 02, 2017 -- Fluidigm Corporation (NASDAQ:FLDM) announced today that its tax benefit preservation plan had expired pursuant to its terms, effectively terminating the plan as of August 1, 2017. Stockholders are not required to take any action as a result of this expiration.
In connection with the expiration of the tax benefit preservation plan, Fluidigm will be taking routine actions to voluntarily deregister the related preferred share purchase rights under the Securities Exchange Act of 1934, and to delist the preferred share purchase rights from NASDAQ. These actions are administrative in nature and will have no effect on Fluidigm’s common stock, which continues to be listed on NASDAQ.
About Fluidigm
Fluidigm (NASDAQ:FLDM) develops, manufactures, and markets life science analytical and preparatory systems for growth markets such as single-cell biology and production genomics. We sell to leading academic institutions, clinical laboratories, and pharmaceutical, biotechnology, and agricultural biotechnology companies worldwide. Our systems are based on proprietary microfluidics and multiparameter mass cytometry technology and are designed to significantly simplify experimental workflow, increase throughput, and reduce costs while providing excellent data quality. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures.
We use our website (www.fluidigm.com), corporate Twitter account (@fluidigm), Facebook page (https://www.facebook.com/Fluidigm), and LinkedIn page (https://www.linkedin.com/company/fluidigm-corporation) as channels of distribution of information about our products, our planned financial and other announcements, our attendance at upcoming investor and industry conferences, and other matters. Such information may be deemed material information, and we may use these channels to comply with our disclosure obligations under Regulation FD. Therefore, investors should monitor our website and our social media accounts in addition to following our press releases, SEC filings, public conference calls, and webcasts.
Fluidigm and the Fluidigm logo are trademarks or registered trademarks of Fluidigm Corporation.
Contact Fluidigm Corporation Ana Petrovic Director, Corporate Development and Investor Relations 650.243.6628 (Office) [email protected]
